TecDAX

ZEISS Announces U.S. FDA Clearance of the QUATERA 700, a Revolution in Phaco Technology

Retrieved on: 
Wednesday, April 20, 2022
CEO, Ophthalmology, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Center, TecDAX, Group, Doctor of Philosophy, Sale, Patient, Carl Zeiss AG, MDAX, OR, Surgeon, Efficiency, ISIN, Technology, Application, Health, Company, Eye, Solution, Microsurgery, ZEISS, Carin, Multimedia, FDA, Quality of life, IOP, Pharmaceutical industry, Medical imaging, MD, Research

JENA, Germany and DUBLIN, Ireland , April 20, 2022 /PRNewswire/ -- Today, ZEISS Medical Technology announced the U.S. Food and Drug Administration (FDA) has cleared the QUATERA® 700*, a revolution in phaco technology. It includes the ZEISS patented QUATTRO Pump® which delivers an exceptional level of chamber stability independent of intra-ocular pressure (IOP) and flow.

Key Points: 
  • JENA, Germany and DUBLIN, Ireland, April 20, 2022 /PRNewswire/ -- Today, ZEISS Medical Technology announced the U.S. Food and Drug Administration (FDA) has cleared the QUATERA 700 *, a revolution in phaco technology.
  • It includes the ZEISS patented QUATTRO Pump which delivers an exceptional level of chamber stability independent of intra-ocular pressure (IOP) and flow.
  • The ZEISS QUATERA 700 is designed to increase a surgeon's workflow efficiency from the clinic to the operating room (OR), enabling one digitally integrated surgical workflow.
  • 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

ZEISS Announces U.S. FDA Clearance of the QUATERA 700, a Revolution in Phaco Technology

Retrieved on: 
Wednesday, April 20, 2022
CEO, Ophthalmology, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Center, TecDAX, Group, Doctor of Philosophy, Sale, Patient, Carl Zeiss AG, MDAX, OR, Surgeon, Efficiency, ISIN, Technology, Application, Health, Company, Eye, Solution, Microsurgery, ZEISS, Carin, FDA, Quality of life, IOP, Pharmaceutical industry, Medical imaging, MD, Research

JENA, Germany and DUBLIN, Ireland, April 20, 2022 /PRNewswire/ -- Today, ZEISS Medical Technology announced the U.S. Food and Drug Administration (FDA) has cleared the QUATERA® 700*, a revolution in phaco technology. It includes the ZEISS patented QUATTRO Pump® which delivers an exceptional level of chamber stability independent of intra-ocular pressure (IOP) and flow.

Key Points: 
  • JENA, Germany and DUBLIN, Ireland, April 20, 2022 /PRNewswire/ -- Today, ZEISS Medical Technology announced the U.S. Food and Drug Administration (FDA) has cleared the QUATERA 700 *, a revolution in phaco technology.
  • It includes the ZEISS patented QUATTRO Pump which delivers an exceptional level of chamber stability independent of intra-ocular pressure (IOP) and flow.
  • The ZEISS QUATERA 700 is designed to increase a surgeon's workflow efficiency from the clinic to the operating room (OR), enabling one digitally integrated surgical workflow.
  • 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

DGAP-News: Eckert & Ziegler: Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR

Retrieved on: 
Tuesday, April 12, 2022
PAN, Nuclear medicine, Primary aldosteronism, TecDAX, Diagnosis, Radiopharmaceutical, III, APA, European Medicines Agency, Lymphoma, RUMC, Multiple myeloma, Aldosterone, Deutsch, Hypertension, Berlin, Prevalence, ISIN, Inflammation, Radboud University Medical Center, Review, Adrenal insufficiency, CXCR4, EMA, PET, BAH, Patient, Phase, AVS, Pharmaceutical industry, Medical imaging, Conn

Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study.

Key Points: 
  • Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study.
  • Developed by PentixaPharm, PENTIXAFOR is an innovative imaging PET tracer that targets the chemokine-4 receptor (CXCR4) and is used to diagnose various oncological and inflammatory diseases.
  • The CASTUS study is a clinical research programme aiming to evaluate the accuracy of PENTIXAFOR in the diagnosis of primary aldosteronism.
  • Eckert & Ziegler (ISIN DE0005659700, TecDAX), the owner of the rights to the underlying [68Ga]Ga-PentixaFor PET compound, is supporting the RUMC team by providing PENTIXAFOR.

DGAP-News: Eckert & Ziegler with Record Results in FY 2021 and Positive Outlook

Retrieved on: 
Friday, April 1, 2022
USD, Nuclear medicine, Medicine, TecDAX, Radiopharmaceutical, Growth, News, DGAP, Deutsch, Board of directors, ISIN, RTÉ Executive Board, Supervisory board, Income, EUR, Security (finance), Film, Cryptocurrency

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) achieved sales of EUR 180.4 million in fiscal year 2021 (previous year: EUR 176.1 million).

Key Points: 
  • Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) achieved sales of EUR 180.4 million in fiscal year 2021 (previous year: EUR 176.1 million).
  • The consolidated net income for the year reached a new record level of EUR 34.5 million (previous year: EUR 22.9 million) or EUR 1.67 per share (previous year: EUR 1.11).
  • In the Isotope Products segment, sales increased by 7% to EUR 95.8 million.
  • Due to the deconsolidation of the tumor irradiation business, sales in the Medical segment declined by 2% to EUR 84.5 million.

DGAP-News: CANCOM: CANCOM closes financial year 2021 with record EBIT growth of 31 percent and proposes dividend increase to EUR 1.00

Retrieved on: 
Friday, April 1, 2022
Cloud, EBITDA, Company, Organization, COO, Mission statement, Sale, Public sector, Investor, TecDAX, CANCOM, EBITA, MDAX, Frankfurt Stock Exchange, SE, Growth, Cloud computing, CFO, Board of directors, CEO, Solution, Service provider, ISIN, ARR, EBIT, RTÉ Executive Board, Economic development, Supervisory board, EUR, Annual report, Treasury, Annual, A.7, Film, Bookkeeping, Management, Group

- Executive Board forecasts very significant growth in 2022 and proposes dividend increase to EUR 1.00 per share.

Key Points: 
  • - Executive Board forecasts very significant growth in 2022 and proposes dividend increase to EUR 1.00 per share.
  • Munich, Germany, 29 March 2022 - CANCOM Group achieved revenue growth of 10.9 percent in the financial year 2021 with Group revenue of EUR 1,304.5 million (previous year: EUR 1,176.2 million*).
  • At EUR 121.5 million, Group EBITDA was even 21.6 percent above the comparable figure (previous year: EUR 99.9 million*).
  • Cash flow from operating activities increased to EUR 72.3 million in the 2021 financial year (previous year: EUR 68.2 million).

DGAP-News: Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials

Retrieved on: 
Friday, April 1, 2022
Company, Nuclear medicine, Medicine, TecDAX, Radiopharmaceutical, Neoplasm, Deutsch, Cancer, ISIN, Ytterbium, Isotope, Patient, Partnership, Pharmaceutical industry, Medical imaging

Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with the Canadian biotech company Alpha-9 Theranostics Inc. (Alpha-9) a clinical supply agreement for Eckert & Ziegler's medical radioisotope Lutetium-177 (non-carrier-added 177Lu).

Key Points: 
  • Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with the Canadian biotech company Alpha-9 Theranostics Inc. (Alpha-9) a clinical supply agreement for Eckert & Ziegler's medical radioisotope Lutetium-177 (non-carrier-added 177Lu).
  • Eckert & Ziegler has developed a unique, stable and reliable method to produce a highly pure form of Lu-177 n.c.a.
  • which will be used by Alpha-9 for the clinical trials of its therapeutic candidates for solid and hematologic malignancies.
  • Alpha-9 is looking forward to its partnership with Eckert & Ziegler and the potential that this partnership creates to advance radioligand therapy.

DGAP-News: Eckert & Ziegler Extends Supply Agreement with Sirtex Medical to Chinese Market

Retrieved on: 
Friday, April 1, 2022
NICE, Nuclear medicine, TecDAX, Radiopharmaceutical, Liver, III, Growth, Mortality, II, Colorectal cancer, Y-90, News, DGAP, CMC, Deutsch, National Institute, Death, ISIN, SIRT, Liver cancer, Disease, Isotope, GMP, Partnership, Security (finance), Pharmaceutical industry, Sirtex

Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have extended their long-term supply agreement for the use of yttrium-90 in Sirtex microspheres for the treatment of liver cancer to the Chinese market.

Key Points: 
  • Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have extended their long-term supply agreement for the use of yttrium-90 in Sirtex microspheres for the treatment of liver cancer to the Chinese market.
  • From its production facilities in Braunschweig and Boston (MA), USA, Eckert & Ziegler supplies the Sirtex sites in Frankfurt, Boston, and Singapore with yttrium-90.
  • "The signing of this supply agreement reinforces the already strong relationship between the two companies as Sirtex enters the Chinese market", adds Grant Spindler, Global Head of Operations at Sirtex Medical Limited.
  • In Jintan (China), Eckert & Ziegler is investing up to EUR 50 million in the construction of a production facility for radiopharmaceuticals.

DGAP-News: Nemetschek Group: Excellent year 2021 - Double-digit growth with a high profitability expected in 2022

Retrieved on: 
Friday, April 1, 2022
Giant, EBITDA, Entertainment, Quality control, Leadership, Investment, TecDAX, MDAX, Build, Growth, Software as a service, Supervisory board, SME, Red giant, Board of directors, CEO, ZBrush, ISIN, Maxon, Federal Executive Boards, Virtual reality, Software, Animation, Depreciation, COVID-19, Media, Nemetschek, Machine learning, Time, Tax, Solution, EUR, AI, Bookkeeping, Video game, Film, Management, Group, Redshift

The EBITDA margin is expected to remain at a high level between 32% to 33% in 2022.

Key Points: 
  • The EBITDA margin is expected to remain at a high level between 32% to 33% in 2022.
  • Nemetschek will therefore continue its long-standing growth record also in 2022.
  • "In 2021, Nemetschek once again impressively demonstrated its status as one of the leading software providers in the world for all phases in the construction process.
  • The growth at constant exchange rates was therefore slightly above the forecasted corridor of 12% to 14% which was already increased in July 2021.

O2 Telefónica and Mavenir Demonstrate Zero Touch CI/CD Based Operations of IMS Core on Cloud Infrastructure

Retrieved on: 
Friday, March 11, 2022
Networks, Mobile, Wireless, Technology, Telecommunications, Software, Zero, Cloud, Senior, Architecture, Telecommunication, Frankfurt Stock Exchange, Automation, Continuous testing, Open source, Internet, EUR, Mobile virtual network operator, Continuous deployment, Adoption, Network function virtualization, VNF, Computer network, LTE, Group, Software, Global Operations, TecDAX, Telco, GSM, UMTS, Video game console, Mobile phone, Mavenir, O2, Core, Mavenir, O2 Telefónica, MAVENIR, O2 TELEFóNICA

This will streamline operations in O2 Telefnica OpCos with leaner operations, faster deployments, and simplified operational changes in the network.

Key Points: 
  • This will streamline operations in O2 Telefnica OpCos with leaner operations, faster deployments, and simplified operational changes in the network.
  • This is a significant milestone in the evolution of streamlined operations, moving away from manual deployments and reducing human error.
  • Mavenir will work with O2 Telefnica to automate the Network Operations, enabling the transition to the adoption of the virtualized Network Functions.
  • Omar Shahdad, Senior Vice President Global Operations, Mavenir said, We are honored to have been chosen by O2 Telefnica for this vital part of their network simplification journey.

O2 / Telefonica Germany and NEC Showcase Open RAN Capabilities with Germany's First of its Kind Small Cells Deployment

Retrieved on: 
Wednesday, March 2, 2022
RAN, Adoption, NEC, TSE, Industry, Automation, Internet, LTE, Safety, EUR, MIMO, GSM, Architecture, NYSE, TecDAX, Efficiency, Telefónica Germany, Senior, Transport, O2, Telecommunication, Frankfurt Stock Exchange, Group, Descriptive ethics, UMTS, Telefónica, Mobile phone, Electrical wiring, Rail transport

TOKYO, Mar 2, 2022 - (JCN Newswire) - O2 / Telefonica Germany and NEC Corporation (TSE: 6701) announced their successful collaboration in launching the first Open and virtual RAN architecture-based small cells in Germany.

Key Points: 
  • TOKYO, Mar 2, 2022 - (JCN Newswire) - O2 / Telefonica Germany and NEC Corporation (TSE: 6701) announced their successful collaboration in launching the first Open and virtual RAN architecture-based small cells in Germany.
  • In this German deployment, the flexibility of Open RAN is leveraged through the use of small cells to improve capacity in dense, urban areas.
  • One of the key advantages of Open RAN over a traditional architecture is that it allows wider choice of vendor options.
  • The adoption of Open RAN small cells combined with macro cells will pave the way for 5G densification.